Welcome to our dedicated page for Grail news (Ticker: GRAL), a resource for investors and traders seeking the latest updates and insights on Grail stock.
About GRAIL Inc.
GRAIL Inc. (Nasdaq: GRAL) is a pioneering healthcare company dedicated to transforming cancer detection through innovative diagnostic solutions. Headquartered in Menlo Park, California, with additional locations in Washington, D.C., North Carolina, and the United Kingdom, GRAIL's mission is to detect cancer early, when it can be cured. The company leverages cutting-edge next-generation sequencing (NGS), advanced machine learning algorithms, and large-scale clinical studies to develop multi-cancer early detection (MCED) technologies that address some of the most challenging gaps in cancer screening today.
Core Technology and Products
At the heart of GRAIL's offerings is its Galleri® multi-cancer early detection test. This groundbreaking blood-based test identifies DNA shed by cancer cells, known as methylation patterns, to detect a wide range of cancers at earlier stages, including those that currently lack recommended screening protocols. By pinpointing the cancer signal's origin, Galleri provides healthcare providers with actionable insights to guide diagnostic and treatment pathways. The test is designed to complement existing cancer screenings, such as mammograms and colonoscopies, and is recommended for adults aged 50 and older or those with elevated cancer risks.
Clinical Validation and Studies
GRAIL has established itself as a leader in clinical validation through its robust portfolio of large-scale studies, including the PATHFINDER, NHS-Galleri, and REFLECTION trials. These studies, conducted in collaboration with leading healthcare institutions and government health systems, aim to assess the safety, performance, and real-world impact of the Galleri test. For example, the PATHFINDER 2 study enrolled over 35,000 participants in the United States, while the NHS-Galleri trial included more than 140,000 participants in the United Kingdom. These efforts underscore GRAIL’s commitment to generating comprehensive clinical evidence to support regulatory approvals and broaden access to its technologies.
Market Applications and Partnerships
GRAIL's innovations extend beyond diagnostics into the broader realm of precision oncology. Its targeted methylation-based platform supports applications such as minimal residual disease detection, biomarker subtyping, and treatment monitoring. The company collaborates with biopharmaceutical firms, including partnerships with AstraZeneca and Daiichi Sankyo, to integrate its technologies into clinical trials and companion diagnostics. Additionally, GRAIL has secured agreements with major health systems, insurers like TRICARE, and employers to expand access to its Galleri test, demonstrating its growing influence in healthcare delivery.
Industry Significance
Operating at the intersection of biotechnology and healthcare, GRAIL addresses a critical unmet need: the early detection of cancers that are often diagnosed at advanced stages. Its focus on leveraging population-scale data, automation, and machine learning positions it as a key player in the evolving landscape of precision medicine. By reducing the incidence of late-stage cancer diagnoses, GRAIL aims to alleviate the global burden of cancer and improve patient outcomes. The company’s emphasis on health equity, as evidenced by its inclusion of diverse populations in clinical trials, further highlights its commitment to making advanced diagnostics accessible to all.
GRAIL (NASDAQ: GRAL) has announced the granting of equity awards in the form of restricted stock units (RSUs) to 15 newly hired non-executive employees. The inducement grants, totaling 108,450 shares of GRAIL's common stock, were awarded under the company's Inducement Equity Incentive Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
The RSUs feature a four-year vesting schedule, with 25% vesting on February 28, 2026, and subsequent annual vestings on the same date, contingent upon continued employment with GRAIL or its subsidiaries.
GRAIL (Nasdaq: GRAL) has launched Generation Possible, partnering with actress Kate Walsh to raise awareness about multi-cancer early detection (MCED) testing. The initiative highlights the significance of early cancer detection, with Walsh's involvement stemming from her parents' cancer experiences.
Key statistics reveal that 46% of Americans aged 50-75 worry about cancer diagnosis, and approximately 70% of cancer deaths are caused by cancers without recommended screening tests. When detected early, the overall 5-year survival rate is four times higher than late-stage diagnosis.
MCED tests serve as a new screening tool for multiple cancers lacking recommended screening tests today. Available at GenPossible.com, the initiative provides resources including Walsh's personal cancer connection, MCED testing information, and a quiz to determine testing appropriateness. These prescription-only tests are recommended for adults with elevated cancer risk, particularly those 50 or older, as a complement to existing cancer screenings.
GRAIL (Nasdaq: GRAL), a healthcare company focused on early cancer detection, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The company's management will deliver a presentation in Boston on Tuesday, March 4, 2025, at 9:10 a.m. ET.
Interested parties can access both live and replay webcasts through the investor relations section of GRAIL's website at investors.grail.com. The presentation recording will remain available for replay for a minimum of 30 days following the event.
GRAIL (NASDAQ: GRAL) reported strong growth in Q4 and full year 2024, with total revenue increasing 26% to $38.3M in Q4 and 35% to $125.6M for the full year. Galleri® test sales exceeded 137,000 units in 2024, driving U.S. Galleri revenue up 45% year-over-year to $108.6M.
Q4 net loss was $97.1M, including $34.6M in Illumina acquisition-related amortization. Full-year net loss reached $2.0B, primarily due to $1.4B in goodwill and intangible assets impairment. The company ended 2024 with a strong cash position of $767M, extending runway into 2028.
Notable developments include TRICARE Health Insurance adding Galleri as a covered benefit for high-risk patients aged 50+ and a new integration with Quest Diagnostics' ordering system, enabling access through 7,400 patient points nationwide. GRAIL completed study visits for two registrational studies in July and plans to complete its modular PMA submission in H1 2026.
GRAIL (NASDAQ: GRAL) has announced it will release its fourth quarter 2024 financial results after market close on Thursday, February 20, 2025. The healthcare company, focused on early cancer detection, will follow the release with a management-hosted webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET.
The webcast will be accessible through GRAIL's investor relations website at investors.grail.com, with a recorded replay available afterward. Interested parties are advised to register at least ten minutes before the call's scheduled start time through the provided registration link.
GRAIL (NASDAQ: GRAL) and Quest Diagnostics (NYSE: DGX) announced the integration of GRAIL's Galleri® multi-cancer early detection (MCED) test into Quest's test ordering system. This collaboration enables providers to order the Galleri test directly through Quest's Quanum laboratory portal and over 900 electronic health record systems.
The integration makes the test accessible at Quest's 7,400 patient access points nationwide, streamlining the ordering process for over 500,000 healthcare providers. The Galleri test, which detects cancer DNA fragments in blood before symptoms appear, is prescription-only and recommended for adults with elevated cancer risk, particularly those 50 or older.
This development builds upon their existing collaboration since 2021, aiming to improve cancer screening accessibility. The test can detect multiple deadly cancers, including those without current recommended screening tests, which account for nearly 70% of cancer deaths.
GRAIL (NASDAQ: GRAL) published patient-reported outcomes (PRO) from their PATHFINDER study in Lancet Oncology, evaluating patient perspectives on their Galleri® multi-cancer early detection (MCED) blood test. The study assessed participants with cancer signal detected (CSD) and no cancer signal detected (NCSD) over 12 months.
Key findings showed minimal patient distress associated with MCED testing. Most participants with NCSD results reported feeling relieved, while those with CSD results experienced only small negative impacts that returned to baseline within 12 months. The study measured anxiety, distress, uncertainty, health-related quality of life, and satisfaction using three assessment instruments.
High overall satisfaction was reported across all participant groups, regardless of signal detection status. Most participants indicated they were likely to continue with both standard screening and MCED testing in the future.
GRAIL (NASDAQ: GRAL), a healthcare company focused on early cancer detection, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Wednesday, January 15 at 9:00 a.m. PT in San Francisco. Interested parties can access both live and replay webcasts through the investor relations section of GRAIL's website at investors.grail.com. The presentation recording will remain available for a minimum of 30 days following the event.
GRAIL (Nasdaq: GRAL) has announced the granting of equity awards to 46 newly hired non-executive employees. The awards consist of restricted stock units (RSUs) totaling 115,093 shares of GRAIL's common stock. These inducement grants were made under GRAIL's Inducement Equity Incentive Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest over approximately four years, with 25% vesting on November 30, 2025, and the remaining portions vesting annually thereafter, contingent on continued employment with GRAIL or its subsidiaries.
GRAIL (Nasdaq: GRAL) has announced its participation in two upcoming investor conferences. The company will conduct fireside chats at the Piper Sandler 36th Annual Healthcare Conference in New York on December 3 at 1:30 p.m. ET, and at the 7th Annual Evercore ISI HealthCONx Conference in Coral Gables, Florida on December 4 at 3:50 p.m. ET. Both sessions will be available via webcast on GRAIL's investor relations website, with replays accessible for at least 30 days following the events.
FAQ
What is the current stock price of Grail (GRAL)?
What is the market cap of Grail (GRAL)?
What is GRAIL Inc.'s primary mission?
What is the Galleri test?
How does GRAIL differentiate itself in the healthcare industry?
What are some key clinical studies conducted by GRAIL?
Who can benefit from the Galleri test?
What industries does GRAIL collaborate with?
What is GRAIL's approach to health equity?
What regulatory steps has GRAIL taken for the Galleri test?
